Budget impact analysis of antiretroviral less drug regimen simplification in HIV-positive patients on the Italian National Health Service

ClinicoEconomics and Outcomes Research

Volumn 6, Issue , 2014, Pages 409-414

  Restelli, Umberto ^a,b   Andreoni, Massimo ^c   Antinori, Andrea ^d   Bonfanti, Marzia ^b   Di Perri, Giovanni ^e   Galli, Massimo ^f   Lazzarin, Adriano ^g   Rizzardini, Giuliano ^a,f  

^a UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^b CREMS Centre for Research on Health Economics Social and Health Care Management Carlo Cattaneo University LIUC   (Italy)

^c TOR VERGATA UNIVERSITY HOSPITAL   (Italy)

^d NATIONAL INSTITUTE FOR INFECTIOUS DISEASES L SPALLANZANI   (Italy)

^e AMEDEO DI SAVOIA HOSPITAL   (Italy)

^f UNIVERSITY OF MILAN   (Italy)

^g SAN RAFFAELE HOSPITAL   (Italy)

Author keywords

Antiretroviral therapy; Budget impact model; Cost; Dual therapy; Italy; Monotherapy

Indexed keywords

ANTIRETROVIRUS AGENT; ATAZANAVIR; DARUNAVIR; EFAVIRENZ; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; LAMIVUDINE; LOPINAVIR PLUS RITONAVIR; RITONAVIR;

ANTIRETROVIRAL THERAPY LESS DRUG REGIMEN; ARTICLE; BUDGET; DRUG COST; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; ITALIAN NATIONAL HEALTH SERVICE; ITALY; MEDICATION COMPLIANCE; NATIONAL HEALTH SERVICE; NONHUMAN;

EID: 84907667549     PISSN: None     EISSN: 11786981     Source Type: Journal    
DOI: 10.2147/CEOR.S68101     Document Type: Article

References (22)

1. Moore RD, Bartlett JG. Dramatic decline in the HIV-1 RNA level over calendar time in a large urban HIV practice. Clin Infect Dis. 2011;53(6): 600-604.
2. Reina E, San Miguel R, Larrea N, Garcia P, Napal V. Potential for simplification of HIV treatment with boosted protease inhibitor monotherapy. Int J Clin Pharm. 2012;34(6):911-916.
3. Ford N, Flexner C, Vella S, Ripin D, Vitoria M. Optimization and simplification of antiretroviral therapy for adults and children. Curr Opin HIV AIDS. 2013;8(6):591-599.
4. Llibre JM, Cardona G, Santos JR, et al. Antiretroviral treatment switch strategies for lowering the costs of antiretroviral therapy in subjects with suppressed HIV-1 viremia in Spain. Clinicoecon Outcomes Res. 2013;5:215-221.
5. Elzi L, Marzolini C, Furrer H, et al; Swiss HIV Cohort Study. Treatment modification in human immunodeficiency virus-infected individuals starting combination antiretroviral therapy between 2005 and 2008. Arch Intern Med. 2010;170(1):57-65.
6. Arribas JR, Clumeck N, Nelson M, Hill A, van Delft Y, Moecklinghoff C. The MONET trial: week 144 analysis of the efficacy of darunavir/ritonavir (DRV/r) monotherapy versus DRV/r plus two nucleoside reverse transcriptase inhibitors, for patients with viral load,50 HIV-1 RNA copies/mL at baseline. HIV Med. 2012;13(7):398-405.
7. Valantin MA, Lambert-Niclot S, Flandre P, et al; MONOI ANRS 136 Study Group. Long-term efficacy of darunavir/ritonavir monotherapy in patients with HIV-1 viral suppression: week 96 results from the MONOI ANRS 136 study. J Antimicrob Chemother. 2012;67(3):691-695.
8. Bierman WF, van Agtmael MA, Nijhuis M, Danner SA, Boucher CA. HIV monotherapy with ritonavir-boosted protease inhibitors: a systematic review. AIDS. 2009;23(3):279-291.
9. Pulido F, Arribas JR, Delgado R, et al; OK04 Study Group. Lopinavir-ritonavir monotherapy versus lopinavir-ritonavir and two nucleosides for maintenance therapy of HIV. AIDS. 2008;22(2):F1-F9.
10. d’Arminio Monforte A, Gianotti N, Cozzi-Lepri A, et al; ICONA Foundation Cohort. Durability of lopinavir/ritonavir monotherapy in individuals with viral load #50 copies/mL in an observational setting. Antivir Ther. 2014;19(3):319-324.
11. Cossarini F, Salpietro S, Galli L, et al. Monotherapy with atazanavir as a simplification strategy: results from an observational study. J Acquir Immune Defic Syndr. 2012;60(3):e101-e103.
12. Karlström O, Josephson F, Sönnerborg A. Early virologic rebound in a pilot trial of ritonavir-boosted atazanavir as maintenance monotherapy. J Acquir Immune Defic Syndr. 2007;44(4):417-422.
13. Castagna A, Spagnuolo V, Galli L, et al. 48-weeks outcomes of atazanavir/ritonavir monotherapy as maintenance strategy in HIV-1 treated subjects with viral suppression: interim analysis results of the MODAT Study. 14th European AIDS Conference; October 16-19, 2013; Brussels, Belgium. Abstract PS4/2. Available from: http://eacs.multilearning.com/eacs/2013/14th/39215/antonella.castagna.48-weeks.outcomes.of.atazanavir.ritonavir.monotherapy.as.html?history_id=689784. Accessed May 9, 2014.
14. Ministry of Health, Commissione Nazionale per la lotta contro l’AIDS, Consulta delle Associazioni per la lotta contro l’AIDS, Società Italiana di Malattie Infettive e Tropicali. Linee Guida Italiane sull’utilizzo dei farmaci antiretrovirali e sulla gestione diagnostico-clinica delle persone con infezione da HIV-1. Ministero della Salute; 2013. Italian. Available from: http://www.salute.gov.it/imgs/C_17_pubblicazioni_2074_allegato.pdf. Accessed May 9, 2014.
15. Casado JL, de la Calle C, del Palacio M, Perez-Elías MJ, Moreno A, Moreno S. Short communication: lamivudine plus a boosted-protease inhibitor as simplification strategy in HIV-infected patients: proof of concept. AIDS Res Hum Retroviruses. 2013;29(3):588-591.
16. Decreto del commissario ad acta 13 gennaio 2014, n 2. Aggiornamento del decreto “Razionalizzazione dell’uso di farmaci per la terapia antiretrovirale HIV”. Available from: http://www.regione.lazio.it/binary/rl_sanita/tbl_normativa/Decr_U00002_13_1_13_aggiornamento_terapia_HIV.pdf. Accessed May 9, 2014.
17. Di Giambenedetto S, Fabbiani M, Colafigli M, et al. Safety and feasibility of treatment simplification to atazanavir/ritonavir + lamivudine in HIV-infected patients on stable treatment with two nucleos(t)ide reverse transcriptase inhibitors + atazanavir/ritonavir with virological suppression (Atazanavir and Lamivudine for treatment Simplification, AtLaS pilot study). J Antimicrob Chemother. 2013;68(6):1364-1372.
18. Mauskopf JA, Sullivan SD, Annemans L, et al. Principles of good practice for budget impact analysis: report of the ISPOR Task Force on good research practices - budget impact analysis. Value Health. 2007;10(5):336-347.
19. Raimondo M, Camoni L, Regine V, et al. Caratteristiche delle persone che vivono con L’HIV e con L’AIDS in Italia [Characteristics of people living with HIV and AIDS in Italy]. Not Ist Super Sanita. 2013;26(7-8):3-6. Italian.
20. Directorate General for Health of Lombardy Region D.d.g. March 1, 2013 - n 1725 - Approvazione del documento avente ad oggetto “Percorso diagnostico terapeutico (PDT) del paziente affetto da malattia HIV/AIDS. Available from: http://www.ao.lodi.it/infoglueDeliverLive/digitalAssets/102/102169_Percorso_diagnostico_terapeutico_del_paziente_affetto_da_malattia_HIV_AIDS_BURL_4_3_2013.sflb.pdf. Accessed August 1, 2014.
21. Agenzia Italiana del Farmaco. L’uso dei farmaci in Italia - Rapporto Nazionale Anno 2012. Roma; 2013. Available from: http://www.agenziafarmaco.gov.it/sites/default/files/Rapporto_OsMed_2012.pdf. Accessed May 9, 2014.
22. Angeletti C, Pezzotti P, Antinori A, et al. Antiretroviral treatment-based cost saving interventions may offset expenses for new patients and earlier treatment start. HIV Med. 2014;15(3):165-174.